Viveve Medical (VIVE) 10-Q 8 Nov 17 2017 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2017	Nov. 07, 2017
Document Information [Line Items]
Entity Registrant Name	VIVEVE MEDICAL, INC.
Entity Central Index Key	879,682
Trading Symbol	vive
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		19,426,415
Document Type	10-Q
Document Period End Date	Sep. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q3
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 19,207	$ 8,086	[1]
Accounts receivable	4,833	2,091	[1]
Inventory	1,903	2,687	[1]
Prepaid expenses and other current assets	3,217	1,066	[1]
Total current assets	29,160	13,930	[1]
Property and equipment, net	1,337	483	[1]
Investment in limited liability company	2,500
Other assets	112	136	[1]
Total assets	33,109	14,549	[1]
Current liabilities:
Accounts payable	3,569	3,086	[1]
Accrued liabilities	3,933	2,186	[1]
Note payable, current portion		1,867	[1]
Total current liabilities	7,502	7,139	[1]
Note payable, noncurrent portion	18,665	7,762	[1]
Other noncurrent liabilities	77	53	[1]
Total liabilities	26,244	14,954	[1]
Commitments and contingences (Note 7)
Stockholders’ equity (deficit):
Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of September 30, 2017 and December 31, 2016; no shares issued
Common stock, $0.0001 par value; 75,000,000 shares authorized as of September 30, 2017 and December 31, 2016; 19,418,531 and 10,661,201 shares issued and outstanding as of September 30, 2017 and December 31, 2016, respectively	2	1	[1]
Additional paid-in capital	102,220	68,216	[1]
Accumulated deficit	(95,357)	(68,622)	[1]
Total stockholders’ equity (deficit)	6,865	(405)	[1]
Total liabilities and stockholders’ equity (deficit)	$ 33,109	$ 14,549	[1]
[1]	The condensed consolidated balance sheet as of December 31, 2016 has been derived from the audited consolidated financial statements as of that date.

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2017	Dec. 31, 2016
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	75,000,000	75,000,000
Common stock, shares issued (in shares)	19,418,531	10,661,201
Common stock, shares outstanding (in shares)	19,418,531	10,661,201

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Revenue	$ 4,070	$ 1,849	$ 10,187	$ 4,689
Cost of revenue	2,059	1,158	5,515	3,116
Gross profit	2,011	691	4,672	1,573
Operating expenses:
Research and development	3,464	2,054	9,292	6,313
Selling, general and administrative	7,369	3,272	19,681	8,435
Total operating expenses	10,833	5,326	28,973	14,748
Loss from operations	(8,822)	(4,635)	(24,301)	(13,175)
Interest expense, net	(777)	(221)	(2,385)	(1,094)
Other expense, net	(16)	(13)	(49)	(22)
Comprehensive and net loss	$ (9,615)	$ (4,869)	$ (26,735)	$ (14,291)
Net loss per share:
Basic and diluted (in dollars per share)	$ (0.50)	$ (0.46)	$ (1.59)	$ (1.63)
Weighted average shares used in computing net loss per common share:
Basic and diluted (in shares)	19,408,920	10,630,468	16,843,706	8,741,667

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2017		Sep. 30, 2016
Cash flows from operating activities:
Net loss	$ (26,735)		$ (14,291)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	318		78
Stock-based compensation	1,314		662
Fair value of common stock issued	260
Fair value of warrants issued			162
Non-cash interest expense	762		422
Changes in assets and liabilities:
Accounts receivable	(2,742)		(1,214)
Inventory	422		76
Prepaid expenses and other current assets	(2,151)		(70)
Other noncurrent assets	24		5
Accounts payable	483		1,045
Accrued and other liabilities	1,747		931
Other noncurrent liabilities	24
Net cash used in operating activities	(26,274)		(12,194)
Cash flows from investing activities:
Investment in limited liability company	(2,500)
Purchase of property and equipment	(810)		(224)
Net cash used in investing activities	(3,310)		(224)
Cash flows from financing activities:
Proceeds from sale of common stock, net of issuance costs	31,440		13,886
Proceeds from note payable	19,214		9,910
Repayments of note payable	(10,000)		(4,833)
Proceeds from exercise of warrant	20		92
Proceeds from exercise of stock options	31		14
Net cash provided by financing activities	40,705		19,069
Net increase in cash and cash equivalents	11,121		6,651
Cash and cash equivalents - beginning of period	8,086	[1]	7,360
Cash and cash equivalents - end of period	19,207		14,011
Supplemental disclosure:
Cash paid for interest	1,619		636
Cash paid for income taxes			1
Supplemental disclosure of cash flow information as of end of period:
Issuance of warrants in connection with note payable	940		350
Net transfer of equipment from inventory to property and equipment	362		60
Issuance of note payable in settlement of accrued interest	285
Restricted stock awards granted to employees for 2015 accrued bonuses			$ 246
[1]	The condensed consolidated balance sheet as of December 31, 2016 has been derived from the audited consolidated financial statements as of that date.

Note 1 - The Company and Basis

Note 1 - The Company and Basis of Presentation	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. The Company and Basis of Presentation Viveve Medical, Inc. (“Viveve Medical”, the “Company”, “we”, “our”, or “us”) competes in the women’s health industry in some countries by marketing Geneveve™ as a way to improve the overall sexual well-being and quality of life of women suffering from vaginal laxity. Public Offering On March 22, 2017, “March 2017 8,625,000 ’ overallotment option, at a public offering price of $4.00 $34,500,000. $31,440,000. On June 17, 2016, “June 2016 3,105,000 ’ overallotment option, at a public offering price of $5.00 $15,525,000. $13,886,000. Change of Corporate Domicile On May 9, 2016, the Company filed the necessary Application for Authorization to Continue into Another Jurisdiction and Statutory Declaration with the Yukon registrar. On May 10, 2016, $0.0001 Interim Unaudited Financial Information The accompanying unaudited condensed consolidated financial statements of Viveve Medical have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10 8 03 X. not The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Annual Report on Form 10 December 31, 2016, February 16, 2017. three nine September 30, 2017 not December 31, 2017 Liquidity Since inception we have funded our operations primarily through sales of common and preferred stock and borrowing arrangements. We have incurred net losses since our inception, and as of September 30, 2017 $95. 4 March 2017 6 10 December 31, 2016, no may may not September 30, 2017, $19.2 $10.0

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies Financial Statement Presentation The condensed consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries, Viveve, Inc. and Viveve BV. All significant intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses and the related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not may Concentration of Credit Risk and Other Risks and Uncertainties To achieve profitable operations, the Company must successfully develop, manufacture, and market its products. There can be no ’s financial results, financial position, and future cash flows. The Company ’s products likely require clearance or approval from the U.S. Food and Drug Administration or other international regulatory agencies prior to commencing commercial sales. There can be no The Company is subject to risks common to companies in the medical device industry including, but not ’s ultimate success is dependent upon its ability to raise additional capital and to successfully develop and market its products. The Company designs, develops, manufactures and markets a medical device for the non-invasive treatment of vaginal introital laxity, for improved sexual function, and for vaginal rejuvenation, depending on the relevant country-specific clearance or approval, that it refers to as Geneveve™. Geneveve includes three third In the U.S., the Company sells its products primarily through a direct sales force to health care practitioners. Outside the U.S., the Company sells through an extensive network of distribution partners. During the three September 30, 2017, two 38% three September 30, 2016, two 89% nine September 30, 2017, three 38% nine September 30, 2016, three 83% There were no 10% ’s revenue during the three nine September 30, 2017 2016. As of September 30, 2017, three 53% December 31, 2016, three 81% Revenue Recognition The Company recognizes revenue from the sale of its products, the Viveve System, single-use treatment tips and ancillary consumables. Revenue is recognized upon shipment, provided that persuasive evidence of an arrangement exists, the price is fixed or determinable and collection of the resulting receivable is reasonably assured. Sales of our products are subject to regulatory requirements that vary from country to country. The Company has regulatory clearance, or can sell its products without a clearance, in many countries throughout the world, including countries within the following regions: North America, Latin America, Europe, the Middle East and Asia Pacific. The Company does not Customer Advance Payments From time to time, customers will pay for a portion of the products ordered in advance. Upon receipt of such payments, the Company records the customer advance payment as a component of accrued liabilities. The Company will remove the customer advance payment from accrued liabilities when revenue is recognized upon shipment of the products. Investments in Unconsolidated Affiliates The Company uses the equity method to account for its investments in entities that it does not 1 ’ net income or losses after the date of investment, ( 2 3 The Company assesses the potential impairment of the equity method investments when indicators such as a history of operating losses, a negative earnings and cash flow outlook, and the financial condition and prospects for the investee ’s business segment might indicate a loss in value. The carrying value of the investments are reviewed annually for changes in circumstances or the occurrence of events that suggest the investment may not three nine September 30, 2017, no Product Warranty The Company ’s products are generally subject to a one not Comprehensive Loss Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may three nine September 30, 2017 2016, Net Loss per Share The Company ’s basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share is computed by giving effect to all potentially dilutive common stock equivalents outstanding during the period. For purposes of this calculation, stock options and warrants to purchase common stock and restricted common stock awards are considered common stock equivalents. For periods in which the Company has reported net losses, diluted net loss per share is the same as basic net loss per share, since dilutive common shares are not The following securities were excluded from the calculation of net loss per share because the inclusion would be anti-dilutive. Nine Months Ended September 30, 2017 2016 Stock options to purchase common stock 2,489,979 1,315,808 Warrants to purchase common stock 642,622 425,274 Restricted common stock awards - 64,405 Recently Issued and Adopted Accounting Standards In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014 09, 606 five not December 15, 2017. January 1, 2017 January 1, 2018, January 1, 2017 ( 2015 14 2016 08 2016 10 2016 10 May 2016, 2016 12, 606 not May 2014. The Company has set up a team for the implementation of the new revenue recognition accounting standard. Based on preliminary analysis, the Company expects that the new standard will not . The Company will adopt this new standard effective January 1, 2018. not In February 2016, 2016 02, “Leases (Topic 842 December 15, 2018, In August 2016, No. 2016 15, 230 This guidance addresses specific cash flow issues with the objective of reducing the diversity in practice for the treatment of these issues. The areas identified include: debt prepayment or debt extinguishment costs; settlement of zero December 15, 2017, We have reviewed other recent accounting pronouncements and concluded they are either not no

Note 3 - Fair Value Measurement

Note 3 - Fair Value Measurements	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Fair Value Disclosures [Text Block]	3. Fair Value Measurements The Company recognizes and discloses the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 3 Level 1 Inputs used to measure fair value are unadjusted quoted prices that are available in active markets for the identical assets or liabilities as of the reporting date. Therefore, determining fair value for Level 1 not not Level 2 Pricing is provided by third not Level 3 Inputs used to measure fair value are unobservable inputs that are supported by little or no ’s estimates of market participant assumptions. The determination of fair value for Level 3 Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. There were no September 30, 2017 December 31, 2016. The carrying amounts of the Company ’s financial assets and liabilities, including cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses as of September 30, 2017 December 31, 2016

Note 4 - Investment in Limited

Note 4 - Investment in Limited Liability Company	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Equity Method Investments and Joint Ventures Disclosure [Text Block]	4. Investment in Limited Liability Company On August 8 , 2017, Under the terms of the Distributorship Agreement, ICM agreed to not third not The Company has a minimum purchase requirement to purchase a certain quantity of ICM products per month during the term of this Distributorship Agreement. In addition, the parties agreed to certain mutual marketing obligations to promote sales of the licensed products. In connection with the Distributorship Agreement, the Company also entered into a Membership Unit Subscription Agreement with ICM and the associated limited liability company operating agreement of ICM, pursuant to which the Company invested $2,500,000 not three nine September 30, 2017

Note 5 - Accrued Liabilities

Note 5 - Accrued Liabilities	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	5 . Accrued Liabilities Accrued liabilities consisted of the following (in thousands): September 30, December 31, 2017 2016 Accrued professional fees $ 1,185 $ 483 Accrued bonuses 873 1,102 Accrued sales commission 592 115 Accrued payroll and other related expenses 458 274 Accrued interest 436 65 Accrued sales & use tax 180 39 Other accruals 209 108 Total accrued liabilities $ 3,933 $ 2,186

Note 6 - Note Payable

Note 6 - Note Payable	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Debt Disclosure [Text Block]	6 . Note Payable On June 20, 2016, January 13, 2017 ( “2016 $10,000,000 two $7,500,000 $2,500,000. $10,000,000 June 20, 2016. 2016 In addition to all outstanding principal and accrued interest on the term loan, the terms of the loan required the Company to pay a final payment fee equal to 4.00% 2016 May 2017. In connection with the 2016 10 100,402 ’s common stock at an exercise price of $4.98 8 On May 22, 2017, “2017 $20,000,000 $10,000,000 $30,000,000 September 17, 2018, minimum net revenue amounts from the Company’s products of at least $16,000,000 twelve 12 June 30, 2018 $60,000,000 thirty 30 second A portion of the initial loan proceeds were used to repay all of the amounts owed by the Company under its existing 2016 2017 may The 2017 six four 2017 12.50%, 4.0% may, nine September 30, 2017, $285,000 September 30, 2017. 5% September 30, 2017, The Company may 2017 first five no As security for its obligations under the 2017 ’s assets, including intellectual property. The terms of the 2017 $2.0 2022, not 2.0 2017 ’s ability to, among other things, incur indebtedness, grant liens, merge or consolidate, dispose of assets, make investments, make acquisitions, enter into transactions with affiliates, pay dividends or make distributions, license intellectual property rights on an exclusive basis or repurchase stock, in each case subject to customary exceptions. As of September 30, 2017, In connection with the 2017 two 10 222,049 ’s common stock at an exercise price of $9.50 8 As of September 30, 2017, Year Ending December 31, 2017 (remaining 3 months) $ 441 2018 1,793 2019 1,867 2020 1,949 2021 11,204 Thereafter 17,154 Total payments 34,408 Less: Amount representing interest (14,123 ) Present value of obligations 20,285 Less: Unamortized debt discount (1,620 ) Note payable, noncurrent portion $ 18,665

Note 7 - Commitments and Contin

Note 7 - Commitments and Contingencies	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	7. Operating Lease In January 2012, September 2016, March 2012 March 2018. On February 1, 2017, 12,400 ’s corporate headquarters to Englewood, Colorado (the “Sublease Premises”), which was effective as of January 26, 2017. June 1, 2017 May 2020. June 2017. The monthly base rent under the Sublease is equal to $20.50 first $21.12 $21.75 second third $22,000. $88,000 Rent expense for the three September 30, 2017 2016 $138,000 $55,000, nine September 30, 2017 2016 $305,000 $164,000, As of September 30, 2017, Year Ending December 31, 2017 (remaining 3 months) $ 145 2018 338 2019 264 2020 112 Total minimum lease payments $ 859 Indemnification Agreements The Company enters into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with performance of services within the scope of the agreement, breach of the agreement by the Company, or noncompliance of regulations or laws by the Company, in all cases provided the indemnified party has not not ’s negligence or willful malfeasance. The term of these indemnification agreements is generally perpetual any time after the execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these arrangements is not Loss Contingencies The Company is or has been subject to proceedings, lawsuits and other claims arising in the ordinary course of business. The Company evaluates contingent liabilities, including threatened or pending litigation, for potential losses. If the potential loss from any claim or legal proceeding in considered probable and the amount can be estimated, the Company accrues a liability for the estimated loss. Because of uncertainties related to these matters, accruals are based upon the best information available. For potential losses for which there is a reasonable possibility (meaning the likelihood is more than remote but less than probable) that a loss exists, the Company will disclose an estimate of the potential loss or range of such potential loss or include a statement that an estimate of the potential loss cannot be made. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation and may Management does not

Note 8 - Common Stock

Note 8 - Common Stock	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	8 . Common Stock On May 19, 2017, 35,000 $7.42 $260,000. On March 22, 2017, March 2017 8,625,000 ’ overallotment option, at a public offering price of $4.00 $34,500,000. $31,440,000. On June 17, 2016, June 2016 3,105,000 ’ overallotment option, at a public offering price of $5.00 $15,525,000. $13,886,000. Warrants for Common Stock As of September 30, 2017, Number of Shares Outstanding Exercisable Expiration Exercise Under Issuance Date for Date Price Warrants September 2014 Common Shares September 23, 2019 $ 4.24 86,831 October 2014 Common Shares October 13, 2019 $ 4.24 29,000 November 2014 Common Shares November 12, 2019 $ 4.24 12,500 February 2015 Common Shares February 17, 2025 $ 4.00 75,697 March 2015 Common Shares March 26, 2025 $ 2.72 1,454 May 2015 Common Shares May 12, 2025 $ 4.24 36,229 May 2015 Common Shares May 17, 2020 $ 4.24 21,585 December 2015 Common Shares December 16, 2025 $ 5.60 26,875 April 2016 Common Shares April 1, 2026 $ 6.08 25,000 May 2016 Common Shares May 11, 2021 $ 7.74 5,000 June 2016 Common Shares June 20, 2026 $ 4.98 100,402 May 2017 Common Shares May 25, 2027 $ 9.50 222,049 642,622 In connection with the Loan and Security Agreement entered into on September 30, 2014, February 19, 2015, May 14, 2015, November 30, 2015 March 18, 2016 ( “2014 sor in interest by merger to Square 1 58,962 $4.24 June 2016 2016 June 30, 2016. three nine September 30, 2016, zero $387,000, August 2016 17,295 In conjunction with the second 2014 May 2015, lender to purchase a total of 3,125 $2.96 September 30, 2015. July 2016 885 In connection with the 2016 100,402 $4.98 $350,000. $90,000, May 2017 2017 three June 30, 2017. three nine September 30, 2017, zero $371,000 three nine September 30, 2016, $35,000 September 30, 2017, 2016 zero In connection with the 2017 222,049, $9.50 ten in whole or in part. The Company determined the fair value of the warrants on the date of issuance to be $940,000 0%, 55.1%, 2.25% ten $786,000, three nine September 30, 2017, $68,000 $106,000 September 30, 2017, $1,620,000. A total of 4,701 25,268 September 30, 2014, nine September 30, 2017 2016, No nine September 30, 2017. 1,094 two October 2014 nine September 30, 2016 not The stock-based compensation expense related to warrants issued was zero both the three September 30, 2017 2016. zero $162,000 nine September 30, 2017 2016,

Note 9 - Summary of Stock Optio

Note 9 - Summary of Stock Options	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	9 . Summary of Stock Options Stock Option Plans The Company has issued equity awards in the form of stock options and restricted stock awards from three ’s 2005 “2005 2006 “2006 2013 “2013 There are currently no 2005 no The 2006 and was terminated in conjunction with the merger that took place on September 23, 2014 2006 2006 2006 38,378 no $10.49 5.13 The 2013 the Company’s board of directors and approved by its stockholders. The 2013 2013 may may may 2013 may not 10 may four may 424 10% no 110% not five On August 22, 2016, ’s stockholders approved an amendment to the 2013 2013 first January, 2013 4% December 23, 2016, 2017 2013 523,209 2,000,000 2,523,209 January 1, 2017. August 15, 2017, 2013 2013 2,523,209 4,000,000 As of September 30, 2017, 2013 2,451,601 1,408,655 $5.80 8.76 Activity under the 2005 2006 2013 Nine Months Ended September 30, 2017 Weighted Weighted Average Aggregate Number Average Remaining Intrinsic of Exercise Contractual Value Shares Price Term (years) (in thousands) Options outstanding, beginning of period 1,909,764 $ 6.19 9.12 $ 211,396 Options granted 739,985 $ 5.86 Options exercised (7,730 ) $ 4.02 Options cancelled (152,040 ) $ 9.82 Options outstanding, end of period 2,489,979 $ 5.88 8.70 $ 387,178 Vested and exercisable and expected to vest, end of period 2,337,350 $ 5.88 8.67 $ 369,478 Vested and exercisable, end of period 734,721 $ 5.90 7.81 $ 162,632 The aggregate intrinsic value reflects the difference between the exercise price of the underlying stock options and the Company ’s closing share price as of September 30, 2017. The options outstanding and exercisable as of September 30, 2017 Options Outstanding Options Exercisable Weighted Number Weighted Average Number Weighted Outstanding Average Remaining Exercisable Average Range of as of Exercise Contractual as of Exercise Exercise Prices September 30, 2017 Price Term (Years) September 30, 2017 Price $2.64 12,500 $ 2.64 7.62 7,553 $ 2.64 $3.68 - $3.76 66,876 $ 3.76 7.35 43,191 $ 3.76 $4.46 - $4.92 400,329 $ 4.63 8.25 161,941 $ 4.77 $5.22 567,679 $ 5.22 9.20 108,555 $ 5.22 $5.58 - $5.67 254,000 $ 5.62 9.93 - $ - $6.00 557,753 $ 6.00 8.22 244,023 $ 6.00 $6.24 - $6.61 150,639 $ 6.44 8.21 45,574 $ 6.34 $7.00 - $7.92 441,825 $ 7.65 9.10 85,506 $ 7.72 $9.92 38,135 $ 9.92 5.14 38,135 $ 9.92 $56.00 - $296.00 243 $ 100.46 3.21 243 $ 100.46 2,489,979 $ 5.88 8.70 734,721 $ 5.90 Restricted Stock Awards In January 2016, 39,494 2013 2015 $6.24 ’s common stock on the award date. A total of 89 September 2016. one January 2017 39,405 In August 2016, 5,998 2013 $7.89 ’s common stock on the award date. The RSAs were fully vested on the date of grant and 5,998 In September 2016, 25,000 $7.58 ’s common stock on the award date. The RSA vests over one 1/4 th September 30, 2017, 25,000 In November 2016, 6,544 2013 $5.91 ’s common stock on the award date. The RSAs were fully vested on the date of grant and 6,544 In May 2017, 4,797 2013 $7.07 ’s common stock on the award date. The RSAs were fully vested on the date of grant and 4,797 In September 2017, 6,947 2013 $5.58 ’s common stock on the award date. The RSAs were fully vested on the date of grant and 6,947 The re were zero September 30, 2017. 2017 In August 2017, ’s 2017 “2017 400,000 2017 may 2,000 2017 85% first three first 2017 October 1, 2017 December 31, 2017. Stock-Based Compensation During the three September 30, 2017 2016, 305,000 220,915 $3.19 $3.58 nine September 30, 2017 2016, 720,110 378,932 $2.83 $3.54 7,730 3,020 nine September 30, 2017 2016, nine September 30, 2017 2016 $31,000 $5,000, The Company estimated the fair value of stock options using the Black-Scholes option pricing model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of employee stock options granted was estimated using the following weighted average assumptions: Three Months Ended Nine Months Ended September 30, September 30, 2017 2016 2017 2016 Expected term (in years) 5 5 5 5 Average volatility 64 % 46 % 55 % 54 % Risk-free interest rate 1.73 % 1.14 % 1.83 % 1.31 % Dividend yield 0 % 0 % 0 % 0 % During the three nine September 30, 2017, 14,000 19,875 $3.66 $4.09, three nine September 30, 2016, 50,000 $4.81 no nine September 30, 2017 2016. Option-pricing models require the input of various subjective assumptions, including the option ’s expected life and the price volatility of the underlying stock. The expected stock price volatility is based on analysis of the Company’s stock price history over a period commensurate with the expected term of the options, trading volume of comparable companies’ stock, look-back volatilities and Company specific events that affected volatility in a prior period. The expected term of employee stock options represents the weighted average period the stock options are expected to remain outstanding and is based on the history of exercises and cancellations on all past option grants made by the Company, the contractual term, the vesting period and the expected remaining term of the outstanding options. The risk-free interest rate is based on the U.S. Treasury interest rates whose term is consistent with the expected life of the stock options. No not not The following table shows stock-based compensation expense included in the condensed consolidated statements of operations for the three nine September 30, 2017 2016 Three Months Ended Nine Months Ended September 30, September 30, 2017 2016 2017 2016 Cost of revenue $ 5 $ - $ 12 $ - Research and development 62 31 170 80 Selling, general and administrative 420 241 1,132 582 Total $ 487 $ 272 $ 1,314 $ 662 As of September 30, 2017, $4,400,000. 2.86

Note 10 - Income Taxes

Note 10 - Income Taxes	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Income Tax Disclosure [Text Block]	10 . Income Taxes No no For interim periods, the Company estimates its annual effective income tax rate and applies the estimated rate to the year-to-date income or loss before income taxes. The Company also computes the tax provision or benefit related to items reported separately and recognizes the items net of their related tax effect in the interim periods in which they occur. The Company also recognizes the effect of changes in enacted tax laws or rates in the interim periods in which the changes occur. The Company ’s effective tax rate is 0% three nine September 30, 2017 2016. 2017 0%.

Note 11 - Related Party Transac

Note 11 - Related Party Transactions	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	11 . Related Party Transactions In June 2006, October 4, 2007. 300 September 30, 2017, 465 37,500 $2,620,000 $1,816,000 three September 30, 2017 2016, $6,326,000 $3,976,000 nine September 30, 2017 2016, September 30, 2017 December 31, 2016 $781,000 $1,297,000, In connection with the Distributorship Agreement entered into with ICM, the Company also entered into a Membership Unit Subscription Agreement with ICM and the Company invested $2,500,000 4 ent, the Company’s purchases of products from ICM has not three nine September 30, 2017.

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Financial Statement Presentation The condensed consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries, Viveve, Inc. and Viveve BV. All significant intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses and the related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not may
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk and Other Risks and Uncertainties To achieve profitable operations, the Company must successfully develop, manufacture, and market its products. There can be no ’s financial results, financial position, and future cash flows. The Company ’s products likely require clearance or approval from the U.S. Food and Drug Administration or other international regulatory agencies prior to commencing commercial sales. There can be no The Company is subject to risks common to companies in the medical device industry including, but not ’s ultimate success is dependent upon its ability to raise additional capital and to successfully develop and market its products. The Company designs, develops, manufactures and markets a medical device for the non-invasive treatment of vaginal introital laxity, for improved sexual function, and for vaginal rejuvenation, depending on the relevant country-specific clearance or approval, that it refers to as Geneveve™. Geneveve includes three third In the U.S., the Company sells its products primarily through a direct sales force to health care practitioners. Outside the U.S., the Company sells through an extensive network of distribution partners. During the three September 30, 2017, two 38% three September 30, 2016, two 89% nine September 30, 2017, three 38% nine September 30, 2016, three 83% There were no 10% ’s revenue during the three nine September 30, 2017 2016. As of September 30, 2017, three 53% December 31, 2016, three 81%
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition The Company recognizes revenue from the sale of its products, the Viveve System, single-use treatment tips and ancillary consumables. Revenue is recognized upon shipment, provided that persuasive evidence of an arrangement exists, the price is fixed or determinable and collection of the resulting receivable is reasonably assured. Sales of our products are subject to regulatory requirements that vary from country to country. The Company has regulatory clearance, or can sell its products without a clearance, in many countries throughout the world, including countries within the following regions: North America, Latin America, Europe, the Middle East and Asia Pacific. The Company does not
Customer Advance Payments, Policy [Policy Text Block]	Customer Advance Payments From time to time, customers will pay for a portion of the products ordered in advance. Upon receipt of such payments, the Company records the customer advance payment as a component of accrued liabilities. The Company will remove the customer advance payment from accrued liabilities when revenue is recognized upon shipment of the products.
Equity Method Investments [Policy Text Block]	Investments in Unconsolidated Affiliates The Company uses the equity method to account for its investments in entities that it does not 1 ’ net income or losses after the date of investment, ( 2 3 The Company assesses the potential impairment of the equity method investments when indicators such as a history of operating losses, a negative earnings and cash flow outlook, and the financial condition and prospects for the investee ’s business segment might indicate a loss in value. The carrying value of the investments are reviewed annually for changes in circumstances or the occurrence of events that suggest the investment may not three nine September 30, 2017, no
Standard Product Warranty, Policy [Policy Text Block]	Product Warranty The Company ’s products are generally subject to a one not
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Loss Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may three nine September 30, 2017 2016,
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Share The Company ’s basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share is computed by giving effect to all potentially dilutive common stock equivalents outstanding during the period. For purposes of this calculation, stock options and warrants to purchase common stock and restricted common stock awards are considered common stock equivalents. For periods in which the Company has reported net losses, diluted net loss per share is the same as basic net loss per share, since dilutive common shares are not The following securities were excluded from the calculation of net loss per share because the inclusion would be anti-dilutive. Nine Months Ended September 30, 2017 2016 Stock options to purchase common stock 2,489,979 1,315,808 Warrants to purchase common stock 642,622 425,274 Restricted common stock awards - 64,405
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued and Adopted Accounting Standards In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014 09, 606 five not December 15, 2017. January 1, 2017 January 1, 2018, January 1, 2017 ( 2015 14 2016 08 2016 10 2016 10 May 2016, 2016 12, 606 not May 2014. The Company has set up a team for the implementation of the new revenue recognition accounting standard. Based on preliminary analysis, the Company expects that the new standard will not . The Company will adopt this new standard effective January 1, 2018. not In February 2016, 2016 02, “Leases (Topic 842 December 15, 2018, In August 2016, No. 2016 15, 230 This guidance addresses specific cash flow issues with the objective of reducing the diversity in practice for the treatment of these issues. The areas identified include: debt prepayment or debt extinguishment costs; settlement of zero December 15, 2017, We have reviewed other recent accounting pronouncements and concluded they are either not no

Note 2 - Summary of Significa18

Note 2 - Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2017
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Nine Months Ended September 30, 2017 2016 Stock options to purchase common stock 2,489,979 1,315,808 Warrants to purchase common stock 642,622 425,274 Restricted common stock awards - 64,405

Note 5 - Accrued Liabilities (T

Note 5 - Accrued Liabilities (Tables)	9 Months Ended
	Sep. 30, 2017
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	September 30, December 31, 2017 2016 Accrued professional fees $ 1,185 $ 483 Accrued bonuses 873 1,102 Accrued sales commission 592 115 Accrued payroll and other related expenses 458 274 Accrued interest 436 65 Accrued sales & use tax 180 39 Other accruals 209 108 Total accrued liabilities $ 3,933 $ 2,186

Note 6 - Note Payable (Tables)

Note 6 - Note Payable (Tables)	9 Months Ended
	Sep. 30, 2017
Notes Tables
Schedule of Debt [Table Text Block]	Year Ending December 31, 2017 (remaining 3 months) $ 441 2018 1,793 2019 1,867 2020 1,949 2021 11,204 Thereafter 17,154 Total payments 34,408 Less: Amount representing interest (14,123 ) Present value of obligations 20,285 Less: Unamortized debt discount (1,620 ) Note payable, noncurrent portion $ 18,665

Note 7 - Commitments and Cont21

Note 7 - Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2017
Notes Tables
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Year Ending December 31, 2017 (remaining 3 months) $ 145 2018 338 2019 264 2020 112 Total minimum lease payments $ 859

Note 8 - Common Stock (Tables)

Note 8 - Common Stock (Tables)	9 Months Ended
	Sep. 30, 2017
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Number of Shares Outstanding Exercisable Expiration Exercise Under Issuance Date for Date Price Warrants September 2014 Common Shares September 23, 2019 $ 4.24 86,831 October 2014 Common Shares October 13, 2019 $ 4.24 29,000 November 2014 Common Shares November 12, 2019 $ 4.24 12,500 February 2015 Common Shares February 17, 2025 $ 4.00 75,697 March 2015 Common Shares March 26, 2025 $ 2.72 1,454 May 2015 Common Shares May 12, 2025 $ 4.24 36,229 May 2015 Common Shares May 17, 2020 $ 4.24 21,585 December 2015 Common Shares December 16, 2025 $ 5.60 26,875 April 2016 Common Shares April 1, 2026 $ 6.08 25,000 May 2016 Common Shares May 11, 2021 $ 7.74 5,000 June 2016 Common Shares June 20, 2026 $ 4.98 100,402 May 2017 Common Shares May 25, 2027 $ 9.50 222,049 642,622

Note 9 - Summary of Stock Opt23

Note 9 - Summary of Stock Options (Tables)	9 Months Ended
	Sep. 30, 2017
Notes Tables
Share-based Compensation, Stock Options, Activity [Table Text Block]	Nine Months Ended September 30, 2017 Weighted Weighted Average Aggregate Number Average Remaining Intrinsic of Exercise Contractual Value Shares Price Term (years) (in thousands) Options outstanding, beginning of period 1,909,764 $ 6.19 9.12 $ 211,396 Options granted 739,985 $ 5.86 Options exercised (7,730 ) $ 4.02 Options cancelled (152,040 ) $ 9.82 Options outstanding, end of period 2,489,979 $ 5.88 8.70 $ 387,178 Vested and exercisable and expected to vest, end of period 2,337,350 $ 5.88 8.67 $ 369,478 Vested and exercisable, end of period 734,721 $ 5.90 7.81 $ 162,632
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	Options Outstanding Options Exercisable Weighted Number Weighted Average Number Weighted Outstanding Average Remaining Exercisable Average Range of as of Exercise Contractual as of Exercise Exercise Prices September 30, 2017 Price Term (Years) September 30, 2017 Price $2.64 12,500 $ 2.64 7.62 7,553 $ 2.64 $3.68 - $3.76 66,876 $ 3.76 7.35 43,191 $ 3.76 $4.46 - $4.92 400,329 $ 4.63 8.25 161,941 $ 4.77 $5.22 567,679 $ 5.22 9.20 108,555 $ 5.22 $5.58 - $5.67 254,000 $ 5.62 9.93 - $ - $6.00 557,753 $ 6.00 8.22 244,023 $ 6.00 $6.24 - $6.61 150,639 $ 6.44 8.21 45,574 $ 6.34 $7.00 - $7.92 441,825 $ 7.65 9.10 85,506 $ 7.72 $9.92 38,135 $ 9.92 5.14 38,135 $ 9.92 $56.00 - $296.00 243 $ 100.46 3.21 243 $ 100.46 2,489,979 $ 5.88 8.70 734,721 $ 5.90
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, 2017 2016 2017 2016 Expected term (in years) 5 5 5 5 Average volatility 64 % 46 % 55 % 54 % Risk-free interest rate 1.73 % 1.14 % 1.83 % 1.31 % Dividend yield 0 % 0 % 0 % 0 %
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, 2017 2016 2017 2016 Cost of revenue $ 5 $ - $ 12 $ - Research and development 62 31 170 80 Selling, general and administrative 420 241 1,132 582 Total $ 487 $ 272 $ 1,314 $ 662

Note 1 - The Company and Basi24

Note 1 - The Company and Basis of Presentation (Details Textual) - USD ($)	Mar. 22, 2017	Jun. 17, 2016	Sep. 30, 2017	Sep. 30, 2016	May 22, 2017	Dec. 31, 2016		May 10, 2016	Dec. 31, 2015
Proceeds from Issuance of Common Stock			$ 31,440,000	$ 13,886,000
Common Stock, Par or Stated Value Per Share			$ 0.0001			$ 0.0001		$ 0.0001
Retained Earnings (Accumulated Deficit)			$ (95,357,000)			$ (68,622,000)	[1]
Cash and Cash Equivalents, at Carrying Value			19,207,000	$ 14,011,000		$ 8,086,000	[1]		$ 7,360,000
The 2017 Loan Agreement [Member] | CRG LP [Member]
Debt Agreement, Covenant, Additional Funding			$ 10,000,000		$ 10,000,000
March 2017 Offering [Member]
Stock Issued During Period, Shares, New Issues	8,625,000
Share Price	$ 4
Proceeds from Issuance of Common Stock	$ 34,500,000
Proceeds From Issuance of Common Stock, Net	$ 31,440,000
June 2016 Offering [Member]
Stock Issued During Period, Shares, New Issues		3,105,000
Share Price		$ 5
Proceeds from Issuance of Common Stock		$ 15,525,000
Proceeds From Issuance of Common Stock, Net		$ 13,886,000
[1]	The condensed consolidated balance sheet as of December 31, 2016 has been derived from the audited consolidated financial statements as of that date.

Note 2 - Summary of Significa25

Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Equity Method Investment, Other than Temporary Impairment	$ 0		$ 0
Warranty Period			1 year
Customer Concentration Risk [Member] | Sales Revenue, Net [Member]
Concentration Risk, Number of Customers	2	2	3	3
Concentration Risk, Percentage	38.00%	89.00%	38.00%	83.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member]
Concentration Risk, Number of Customers			3		3
Concentration Risk, Percentage			53.00%		81.00%

Note 2 - Summary of Significa26

Note 2 - Summary of Significant Accounting Policies - Antidilutive Securities (Details) - shares	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Employee Stock Option [Member]
Stock options to purchase common stock (in shares)	2,489,979	1,315,808
Common Stock Warrants [Member]
Stock options to purchase common stock (in shares)	642,622	425,274
Restricted Stock [Member]
Stock options to purchase common stock (in shares)		64,405

Note 4 - Investment in Limite27

Note 4 - Investment in Limited Liability Company (Details Textual) - USD ($)	Aug. 08, 2017	Sep. 30, 2017	Sep. 30, 2016
Payments to Acquire Equity Method Investments		$ 2,500,000
InControl Medical [Member] | Membership Unit Subscription Agreement [Member]
Payments to Acquire Equity Method Investments	$ 2,500,000

Note 5 - Accrued Liabilities -

Note 5 - Accrued Liabilities - Accrued Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Accrued professional fees	$ 1,185	$ 483
Accrued bonuses	873	1,102
Accrued sales commission	592	115
Accrued payroll and other related expenses	458	274
Accrued interest	436	65
Accrued sales & use tax	180	39
Other accruals	209	108
Total accrued liabilities	$ 3,933	$ 2,186	[1]
[1]	The condensed consolidated balance sheet as of December 31, 2016 has been derived from the audited consolidated financial statements as of that date.

Note 6 - Note Payable (Details

Note 6 - Note Payable (Details Textual) - USD ($)	May 22, 2017	Jun. 20, 2016	May 31, 2017	Sep. 30, 2017
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				642,622
June 2016 Issuance Related to 2016 Loan Agreement [Member]
Warrant Term		10 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		100,402		100,402
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 4.98		$ 4.98
May 2017 Issuance Related to 2017 Loan Agreement [Member]
Warrant Term	10 years		10 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	222,049		222,049	222,049
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 9.50		$ 9.50	$ 9.50
Number of Warrants Issued During Period	2
The 2016 Loan Agreement [Member] | Western Alliance Bank [Member]
Debt Instrument, Face Amount		$ 10,000,000
Debt Instrument, Fee, Percentage		4.00%
The 2016 Loan Agreement [Member] | Western Alliance Bank [Member] | First Tranche [Member]
Proceeds from Issuance of Long-term Debt		$ 7,500,000
The 2016 Loan Agreement [Member] | Western Alliance Bank [Member] | Second Tranche [Member]
Proceeds from Issuance of Long-term Debt		$ 2,500,000
The 2017 Loan Agreement [Member] | CRG LP [Member]
Debt Instrument, Face Amount	$ 20,000,000
Debt Agreement, Covenant, Additional Funding	10,000,000			$ 10,000,000
Debt Agreement, Maximum Borrowing Capacity	30,000,000
Debt Instrument, Covenant, Additional Funding, Minimum Net Revenue	16,000,000
Debt Instrument, Covenant, Additional Funding, Minimum Average Market Capitalization	$ 60,000,000
Debt Instrument, Term	6 years
Debt instrument, Interest Only Payment, Period	4 years
Debt Instrument, Interest Rate, Stated Percentage	12.50%
Debt Instrument, Interest Rate, Stated Percentage Deferred During Interest-only Period	4.00%
Paid-in-Kind Interest				$ 285,000
Debt Instrument, Prepayment Fee, Percentage	5.00%
Debt Instrument, Prepayment Fee, Period of Term	5 years
Debt Instrument, Covenant, Cash and Cash Equivalents	$ 2,000,000

Note 6 - Note Payable - Summary

Note 6 - Note Payable - Summary of Note Payable (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016	[1]
2017 (remaining 3 months)	$ 441
2,018	1,793
2,019	1,867
2,020	1,949
2,021	11,204
Thereafter	17,154
Total payments	34,408
Less: Amount representing interest	(14,123)
Present value of obligations	20,285
Less: Unamortized debt discount	(1,620)
Note payable, noncurrent portion	$ 18,665	$ 7,762
[1]	The condensed consolidated balance sheet as of December 31, 2016 has been derived from the audited consolidated financial statements as of that date.

Note 7 - Commitments and Cont31

Note 7 - Commitments and Contingencies (Details Textual)	3 Months Ended		9 Months Ended
	Sep. 30, 2017USD ($)	Sep. 30, 2016USD ($)	Sep. 30, 2017USD ($)	Sep. 30, 2016USD ($)	Feb. 01, 2017USD ($)ft²$ / item
Operating Leases, Rent Expense | $	$ 138,000	$ 55,000	$ 305,000	$ 164,000
Sublease Agreement for Relocation of Headquarters [Member]
Area of Real Estate Property | ft²					12,400
Operating Leases, Monthly Rent Per Rentable Square Foot During First Year | $ / item					20.5
Operating Leases, Monthly Rent Per Rentable Square Foot During Second Year | $ / item					21.12
Operating Leases, Monthly Rent Per Rentable Square Foot During Third Year | $ / item					21.75
Security Deposit | $					$ 22,000
Operating Leases, Allowance for Certain Improvements | $					$ 88,000

Note 7 - Commitments and Cont32

Note 7 - Commitments and Contingencies - Future Minimum Lease Payments (Details) $ in Thousands	Sep. 30, 2017USD ($)
2017 (remaining 3 months)	$ 145
2,018	338
2,019	264
2,020	112
Total minimum lease payments	$ 859

Note 8 - Common Stock (Details

Note 8 - Common Stock (Details Textual) - USD ($)	May 31, 2017	May 22, 2017	Mar. 22, 2017	Jun. 20, 2016	Jun. 17, 2016	May 31, 2017	May 19, 2017	Aug. 30, 2016	Jul. 31, 2016	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	May 31, 2015	Sep. 30, 2014
Proceeds from Issuance of Common Stock												$ 31,440,000	$ 13,886,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights										642,622		642,622
Debt Instrument, Unamortized Discount										$ 1,620,000		$ 1,620,000
Class of Warrants or Rights, Exercises in Period												4,701	25,268
Allocated Share-based Compensation Expense										487,000	$ 272,000	$ 1,314,000	$ 662,000
The 2016 Loan Agreement [Member]
Amortization of Debt Discount (Premium)										0	35,000	371,000	35,000
Debt Issuance Costs, Net				$ 90,000
Debt Instrument, Unamortized Discount										0		0
The 2017 Loan Agreement [Member]
Amortization of Debt Discount (Premium)										68,000		106,000
Debt Issuance Costs, Net	$ 786,000					$ 786,000
Debt Instrument, Unamortized Discount										$ 1,620,000		$ 1,620,000
September 2014 Issuance Related to 2014 Loan Agreement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights															58,962
Class of Warrant or Right, Exercise Price of Warrants or Rights															$ 4.24
Amortization of Debt Discount (Premium)											0		387,000
Stock Issued During Period, Shares, Exercise of Warrants								17,295
May 2015 Issuance Related to 2014 Loan Agreement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights														3,125
Class of Warrant or Right, Exercise Price of Warrants or Rights														$ 2.96
Stock Issued During Period, Shares, Exercise of Warrants									885
June 2016 Issuance Related to 2016 Loan Agreement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				100,402						100,402		100,402
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 4.98						$ 4.98		$ 4.98
Warrants and Rights Outstanding				$ 350,000
Warrant Term				10 years
May 2017 Issuance Related to 2017 Loan Agreement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	222,049	222,049				222,049				222,049		222,049
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 9.50	$ 9.50				$ 9.50				$ 9.50		$ 9.50
Warrants and Rights Outstanding	$ 940,000					$ 940,000
Warrant Term		10 years				10 years
Fair Value Assumptions, Expected Dividend Rate						0.00%
Fair Value Assumptions, Expected Volatility Rate						55.10%
Fair Value Assumptions, Risk Free Interest Rate						2.25%
Fair Value Assumptions, Expected Term	10 years
Allocated Share-based Compensation Expense										$ 0	$ 0	$ 162,000	$ 9
Vendors and Contractors Warrants, October and November 2014 Issuance [Member]
Class of Warrant or Right Number of Securities Called by Warrants or Rights Cancelled In Period												0	1,094
March 2017 Offering [Member]
Stock Issued During Period, Shares, New Issues			8,625,000
Share Price			$ 4
Proceeds from Issuance of Common Stock			$ 34,500,000
Proceeds From Issuance of Common Stock, Net			$ 31,440,000
June 2016 Offering [Member]
Stock Issued During Period, Shares, New Issues					3,105,000
Share Price					$ 5
Proceeds from Issuance of Common Stock					$ 15,525,000
Proceeds From Issuance of Common Stock, Net					$ 13,886,000
Restricted Stock [Member]
Stock Issued During Period, Shares, New Issues							35,000
Shares Issued, Price Per Share							$ 7.42
Stock Issued During Period, Value, New Issues							$ 260,000

Note 8 - Common Stock - Summary

Note 8 - Common Stock - Summary of Outstanding Warrants (Details) - $ / shares	9 Months Ended
	Sep. 30, 2017	May 31, 2017	May 22, 2017	Jun. 20, 2016
Shares Outstanding Under Warrants (in shares)	642,622
September 2014 Issuance Through Private Offering [Member]
Expiration Date	Sep. 23, 2019
Exercise Price (in dollars per share)	$ 4.24
Shares Outstanding Under Warrants (in shares)	86,831
Vendors and Contractor Warrants, October 2014 Issuance [Member]
Expiration Date	Oct. 13, 2019
Exercise Price (in dollars per share)	$ 4.24
Shares Outstanding Under Warrants (in shares)	29,000
Vendors and Contractor Warrants, November 2014 Issuance [Member]
Expiration Date	Nov. 12, 2019
Exercise Price (in dollars per share)	$ 4.24
Shares Outstanding Under Warrants (in shares)	12,500
Employee Performance Bonus Warrants, February 2015 Issuance [Member]
Expiration Date	Feb. 17, 2025
Exercise Price (in dollars per share)	$ 4
Shares Outstanding Under Warrants (in shares)	75,697
Contractor Warrants, March 2015 Issuance [Member]
Expiration Date	Mar. 26, 2025
Exercise Price (in dollars per share)	$ 2.72
Shares Outstanding Under Warrants (in shares)	1,454
Contractor Warrants, May 2015 Issuance [Member]
Expiration Date	May 12, 2025
Exercise Price (in dollars per share)	$ 4.24
Shares Outstanding Under Warrants (in shares)	36,229
May 2015 Issuance Second Contractor [Member]
Expiration Date	May 17, 2020
Exercise Price (in dollars per share)	$ 4.24
Shares Outstanding Under Warrants (in shares)	21,585
Performance Bonus Warrants, December 2015 Issuance [Member]
Expiration Date	Dec. 16, 2025
Exercise Price (in dollars per share)	$ 5.60
Shares Outstanding Under Warrants (in shares)	26,875
Distributor Warrants, April 2016 Issuance [Member]
Expiration Date	Apr. 1, 2026
Exercise Price (in dollars per share)	$ 6.08
Shares Outstanding Under Warrants (in shares)	25,000
Contractor Warrants, May 2016 Issuance [Member]
Expiration Date	May 11, 2021
Exercise Price (in dollars per share)	$ 7.74
Shares Outstanding Under Warrants (in shares)	5,000
June 2016 Issuance Related to 2016 Loan Agreement [Member]
Expiration Date	Jun. 20, 2026
Exercise Price (in dollars per share)	$ 4.98			$ 4.98
Shares Outstanding Under Warrants (in shares)	100,402			100,402
May 2017 Issuance Related to 2017 Loan Agreement [Member]
Expiration Date	May 25, 2027
Exercise Price (in dollars per share)	$ 9.50	$ 9.50	$ 9.50
Shares Outstanding Under Warrants (in shares)	222,049	222,049	222,049

Note 9 - Summary of Stock Opt35

Note 9 - Summary of Stock Options (Details Textual) - USD ($)	Dec. 23, 2016	Aug. 22, 2016	Sep. 30, 2017	Aug. 30, 2017	May 31, 2017	Jan. 31, 2017	Nov. 30, 2016	Sep. 30, 2016	Aug. 31, 2016	Jan. 31, 2016	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Aug. 15, 2017	Aug. 14, 2017	Dec. 22, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number			2,489,979								2,489,979		2,489,979		1,909,764
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price			$ 5.88								$ 5.88		$ 5.88		$ 6.19
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term													8 years 255 days		9 years 43 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross													739,985
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period													7,730
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value													$ 31,000	$ 5,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate											0.00%	0.00%	0.00%	0.00%
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options			$ 4,400,000								$ 4,400,000		$ 4,400,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition													2 years 313 days
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate													0.00%
Two Thousand Five Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number			0								0		0
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant			0								0		0
The 2006 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number			38,378								38,378		38,378
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price			$ 10.49								$ 10.49		$ 10.49
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term													5 years 47 days
The 2013 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number			2,451,601								2,451,601		2,451,601
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price			$ 5.80								$ 5.80		$ 5.80
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term													8 years 277 days
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period													10 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period													4 years
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum													10.00%
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent													110.00%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized, Percentage Increase of Outstanding Common Stock		4.00%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized	523,209
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	2,523,209															4,000,000	2,523,209	2,000,000
Common Stock, Capital Shares Reserved for Future Issuance			1,408,655								1,408,655		1,408,655
The 2013 Plan [Member] | Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross											305,000	220,915	720,110	378,932
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value											$ 3.19	$ 3.58	$ 2.83	$ 3.54
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period													7,730	3,020
The 2013 Plan [Member] | Nonemployees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross											14,000	50,000	19,875	50,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value											$ 3.66	$ 4.81	$ 4.09	$ 4.81
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period													0	0
The 2013 Plan [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number			0								0		0
The 2013 Plan [Member] | Restricted Stock [Member] | Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period										39,494
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value										$ 6.24
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period								89
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period						39,405
The 2013 Plan [Member] | Restricted Stock [Member] | Board Members [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period			6,947		4,797		6,544		5,998
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value			$ 5.58		$ 7.07		$ 5.91		$ 7.89
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period			6,947		4,797		6,544		5,998
The 2013 Plan [Member] | Restricted Stock [Member] | Consultant [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period								1 year
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period								25,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value								$ 7.58
The 2013 Plan [Member] | Holdings Greater Than 10 Percent of Shares Outstanding [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period													5 years
The 2013 Plan [Member] | Quarterly [Member] | Restricted Stock [Member] | Consultant [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period													25,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage								25.00%
2017 Employee Stock Purchase Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance				400,000
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee				2,000
Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date				85.00%
Share-based Compensation Arrangement by Share-based Payment Award, Offering Period				90 days

Note 9 - Summary of Stock Opt36

Note 9 - Summary of Stock Options - Summary of Option Activity Under All Plans (Details) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2017USD ($)$ / sharesshares	Dec. 31, 2016USD ($)$ / sharesshares
Options outstanding, Shares (in shares) | shares	1,909,764
Options outstanding, Weighted average exercise price (in dollars per share) | $ / shares	$ 6.19
Options outstanding, weighted average remaining contractual term (Year)	8 years 255 days	9 years 43 days
Options outstanding, Aggregate Intrinsic Value | $	$ 387,178	$ 211,396
Options granted, Shares (in shares) | shares	739,985
Options granted, Weighted average exercise price (in dollars per share) | $ / shares	$ 5.86
Options exercised, Shares (in shares) | shares	(7,730)
Options exercised, Weighted average exercise price (in dollars per share) | $ / shares	$ 4.02
Options canceled, Shares (in shares) | shares	(152,040)
Options canceled, Weighted average exercise price (in dollars per share) | $ / shares	$ 9.82
Options outstanding, Shares (in shares) | shares	2,489,979	1,909,764
Options outstanding, Weighted average exercise priceod (in dollars per share) | $ / shares	$ 5.88	$ 6.19
Vested and exercisable and expected to vest, end of period, Number Of Shares (in shares) | shares	2,337,350
Vested and exercisable and expected to vest, end of period, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 5.88
Vested and exercisable and expected to vest, end of period, Weighted Average Remaining Contractual Term (Year)	8 years 244 days
Vested and exercisable and expected to vest, end of period, Aggregate Intrinsic Value | $	$ 369,478
Vested and exercisable, end of period, Number Of Shares (in shares) | shares	734,721
Vested and exercisable, end of period, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 5.90
Vested and exercisable, end of period, Weighted Average Remaining Contractual Term (Year)	7 years 295 days
Vested and exercisable, end of period, Aggregate Intrinsic Value | $	$ 162,632

Note 9 - Summary of Stock Opt37

Note 9 - Summary of Stock Options - Summary of Options Outstanding and Exercisable (Details)	9 Months Ended
	Sep. 30, 2017$ / sharesshares
Options outstanding, number (in shares) | shares	2,489,979
Options outstanding, weighted average exercise price (in dollars per share)	$ 5.88
Options outstanding, weighted average remaining contractual term (Year)	8 years 255 days
Options exercisable, number exercisable (in shares) | shares	734,721
Options exercisable, weighted average exercise price (in dollars per share)	$ 5.90
Range One [Member]
Options outstanding, number (in shares) | shares	12,500
Options outstanding, weighted average exercise price (in dollars per share)	$ 2.64
Options outstanding, weighted average remaining contractual term (Year)	7 years 226 days
Options exercisable, number exercisable (in shares) | shares	7,553
Options exercisable, weighted average exercise price (in dollars per share)	$ 2.64
Range Two [Member]
Options outstanding, number (in shares) | shares	66,876
Options outstanding, weighted average exercise price (in dollars per share)	$ 3.76
Options outstanding, weighted average remaining contractual term (Year)	7 years 127 days
Options exercisable, number exercisable (in shares) | shares	43,191
Options exercisable, weighted average exercise price (in dollars per share)	$ 3.76
Exercise price range, lower limit (in dollars per share)	3.68
Exercise price range, upper limit (in dollars per share)	$ 3.76
Range Three [Member]
Options outstanding, number (in shares) | shares	400,329
Options outstanding, weighted average exercise price (in dollars per share)	$ 4.63
Options outstanding, weighted average remaining contractual term (Year)	8 years 91 days
Options exercisable, number exercisable (in shares) | shares	161,941
Options exercisable, weighted average exercise price (in dollars per share)	$ 4.77
Exercise price range, lower limit (in dollars per share)	4.46
Exercise price range, upper limit (in dollars per share)	$ 4.92
Range Four [Member]
Options outstanding, number (in shares) | shares	567,679
Options outstanding, weighted average exercise price (in dollars per share)	$ 5.22
Options outstanding, weighted average remaining contractual term (Year)	9 years 73 days
Options exercisable, number exercisable (in shares) | shares	108,555
Options exercisable, weighted average exercise price (in dollars per share)	$ 5.22
Range Five [Member]
Options outstanding, number (in shares) | shares	254,000
Options outstanding, weighted average exercise price (in dollars per share)	$ 5.62
Options outstanding, weighted average remaining contractual term (Year)	9 years 339 days
Options exercisable, number exercisable (in shares) | shares
Options exercisable, weighted average exercise price (in dollars per share)
Exercise price range, lower limit (in dollars per share)	5.58
Exercise price range, upper limit (in dollars per share)	$ 5.67
Range Six [Member]
Options outstanding, number (in shares) | shares	557,753
Options outstanding, weighted average exercise price (in dollars per share)	$ 6
Options outstanding, weighted average remaining contractual term (Year)	8 years 80 days
Options exercisable, number exercisable (in shares) | shares	244,023
Options exercisable, weighted average exercise price (in dollars per share)	$ 6
Range Seven [Member]
Options outstanding, number (in shares) | shares	150,639
Options outstanding, weighted average exercise price (in dollars per share)	$ 6.44
Options outstanding, weighted average remaining contractual term (Year)	8 years 76 days
Options exercisable, number exercisable (in shares) | shares	45,574
Options exercisable, weighted average exercise price (in dollars per share)	$ 6.34
Exercise price range, lower limit (in dollars per share)	6.24
Exercise price range, upper limit (in dollars per share)	$ 6.61
Range Eight [Member]
Options outstanding, number (in shares) | shares	441,825
Options outstanding, weighted average exercise price (in dollars per share)	$ 7.65
Options outstanding, weighted average remaining contractual term (Year)	9 years 36 days
Options exercisable, number exercisable (in shares) | shares	85,506
Options exercisable, weighted average exercise price (in dollars per share)	$ 7.72
Exercise price range, lower limit (in dollars per share)	7
Exercise price range, upper limit (in dollars per share)	$ 7.92
Range Nine [Member]
Options outstanding, number (in shares) | shares	38,135
Options outstanding, weighted average exercise price (in dollars per share)	$ 9.92
Options outstanding, weighted average remaining contractual term (Year)	5 years 51 days
Options exercisable, number exercisable (in shares) | shares	38,135
Options exercisable, weighted average exercise price (in dollars per share)	$ 9.92
Range Ten [Member]
Options outstanding, number (in shares) | shares	243
Options outstanding, weighted average exercise price (in dollars per share)	$ 100.46
Options outstanding, weighted average remaining contractual term (Year)	3 years 76 days
Options exercisable, number exercisable (in shares) | shares	243
Options exercisable, weighted average exercise price (in dollars per share)	$ 100.46
Exercise price range, lower limit (in dollars per share)	56
Exercise price range, upper limit (in dollars per share)	$ 296

Note 9 - Summary of Stock Opt38

Note 9 - Summary of Stock Options - Valuation Assumptions for Stock Options (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Expected term (in years) (Year)	5 years	5 years	5 years	5 years
Average volatility	64.00%	46.00%	55.00%	54.00%
Risk-free interest rate	1.73%	1.14%	1.83%	1.31%
Dividend yield	0.00%	0.00%	0.00%	0.00%

Note 9 - Summary of Stock Opt39

Note 9 - Summary of Stock Options - Stock-based Compensation Expense Included in the Statement of Income (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Allocated share-based compensation expense	$ 487	$ 272	$ 1,314	$ 662
Cost of Sales [Member]
Allocated share-based compensation expense	5		12
Research and Development Expense [Member]
Allocated share-based compensation expense	62	31	170	80
Selling, General and Administrative Expenses [Member]
Allocated share-based compensation expense	$ 420	$ 241	$ 1,132	$ 582

Note 10 - Income Taxes (Details

Note 10 - Income Taxes (Details Textual)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2017
Effective Income Tax Rate Reconciliation, Percent	0.00%	0.00%	0.00%	0.00%
Scenario, Forecast [Member]
Effective Income Tax Rate Reconciliation, Percent					0.00%

Note 11 - Related Party Trans41

Note 11 - Related Party Transactions (Details Textual) - USD ($)	Aug. 08, 2017	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Dec. 31, 2016
Payments to Acquire Equity Method Investments				$ 2,500,000
InControl Medical [Member] | Membership Unit Subscription Agreement [Member]
Payments to Acquire Equity Method Investments	$ 2,500,000
Stellartech Research Corporation [Member]
Stock Issued During Period, Shares, New Issues						37,500
Related Party Transaction, Amounts of Transaction		$ 2,620,000	$ 1,816,000	6,326,000	$ 3,976,000
Accounts Payable, Related Parties, Current		$ 781,000		$ 781,000		$ 781,000	$ 1,297,000